M. Orozco Levi (Barcelona, Spain), T. Similowski (Paris, France)
Effects of breathing helium-oxygen (He-O2) on expiratory flow-limitation (EFL) in chronic obstructive pulmonary disease (COPD) during quiet breathing (QB)
R. L. Dellaca‘, N. Duffy, A. Aliverti, A. Pedotti, P. M. A. Calverley (Milano, Italy; Liverpool, United Kingdom)
|  |
Relationship between FEV1 and PEF in patients with airways obstruction
A. N. Aggarwal, D. Gupta, D. Behera, S. K. Jindal (Chandigarh, India)
| |
FEF25-75% based on FEV6 is significantly less variable than the traditional FEF25-75%
M. P. Swanney, L. E. Beckert, C. M. Frampton, R. L. Jensen, R. O. Crapo (Christchurch, New Zealand; Salt Lake City, United States Of America)
| |
Value of FEV1/FEV6 in the diagnosis of airway obstruction
S. Wesolowski, P. Boros, M. Franczuk (Warsaw, Poland)
| |
Reactive oxygen and nitrogen species (ROS & RNS) are associated with respiratory muscle dysfunction in severe COPD patients
E. Barreiro, B. De la Puente, J. Minguella, D. Sanchez, J. M. Corominas, S. N. A. Hussain, J. Gea (Barcelona, Spain; Montreal, Canada)
| |
Regional ventilation and perfusion lung scans vs lung function tests by a new ventilation equipment
G. Palmiero, P. Fazzi, E. Borsò, R. Albertelli, C. Giuntini (Pisa, Italy)
| |
Impulse oscillometry parameters in patients with severe COPD after lung volume reduction surgery
L. D. Kiryukhina, G. V. Nikolaev, A. L. Akopov (St Petersburg, Russia)
| |
Air space distribution and mechanical properties of the emphysematous lung in klotho mouse
A. Sato, T. Hirai, S. Muro, A. Imura, Y. I. Nabeshima, M. Mishima (Kyoto, Japan)
| |
FEV1 is not sufficient for assessing bronchodilator reversibility in chronic obstructive pulmonary disease
A. S. Rubin, F. M. B. Tavares, L. C. Correa da Silva (Porto Alegre, Brazil)
| |
Dynamic hyperinflation during the 6-minute walk test and incremental cycling exercise in patients with chronic obstructive pulmonary disease
C. Sanida, S. Abdel Kafi, R. Sergysels, V. Ninane (Brussels, Belgium)
| |
Measuring bronchodilation in COPD clinical trials
Z. L. Borrill, C. M. Houghton, J. Vestbo, A. Woodcock, D. Singh (Manchester, United Kingdom)
| |
The relationship between transfer coefficient for carbon monoxide (KCO), weight and biochemical and morphological parameters in pulmonary emphysema
A. Herrejon, P. Plaza, I. Inchaurraga, J. Palop, C. Morillas, A. Hernandez, R. Blanquer (Valencia, Spain)
| |
Interaction of hemostasis (H) and immune response (IR) in COPD development
A. E. Makarevich (Minsk, Belarus)
| |
Value of ²GOLD² reversibility test criteria in detecting ²reversible² chronic obstructive pulmonary disease (COPD) patients
P. Boros, M. Franczuk, S. Wesolowski (Warsaw, Poland)
| |
The different results of the six minutes walking-test in COPD patients with or without significant improvement of inspiratory capacity after bronchodilator test
M. Biagini, M. Naldi, I. Archinucci, M. Rossi (Arezzo, Siena, Italy)
| |
On efficiently categorising fine and coarse crackles using continuous wavelet transform
S. A. Taplidou, L. J. Hadjileontiadis, V. Gross, T. Penzel, S. M. Panas (Thessaloniki, Greece; Marburg, Germany)
| |
Low-frequency sound transmission in patients with COPD
D. I. Barr, S. Jack, D. Davis, J. E. Earis (Liverpool, Manchester, United Kingdom)
| |
Chest wall, lung and muscle sounds
D. I. Barr, P. Magee, S. Jack, J. E. Earis (Liverpool, United Kingdom)
| |
The evaluation of factors affecting dyspnea and quality of life in COPD patients
G. Demir, B. E. Gulbay, N. Tarakci, O. Akkoca, S. Saryal (Ankara, Turkey)
| |
Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients
M. Polatli, A. Cakir, H. Ozcan, C. Yenisey, O. Cildag, Y. Yenicerioglu (Aydin, Turkey)
| |